Aura Biosciences (AURA) Fundamental Analysis: Revenue, Earnings & Valuation

3.65 / 10

Netural

Fundamental rating is Neutral with a 3.6/10 score. Strengths include cash‑to‑market value and high inventory turnover; weaknesses lie in revenue‑to‑market value and gross profit margin. Overall quality is guarded, indicating limited upside without operational improvements.

Analysis Checks(7/10)

Revenue-MV

Value-0.28

Score1/3

Weight12.47%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value78.03

Score3/3

Weight3.22%

1M Return1.54%

Inventory turnover ratio

Value47.95

Score3/3

Weight16.55%

1M Return6.74%

Gross profit margin (%)

Value36.92

Score1/3

Weight-1.17%

1M Return-0.63%

PB-ROE

Value0.57

Score0/3

Weight8.33%

1M Return3.23%

Income tax / Total profit (%)

Value-0.12

Score2/3

Weight2.21%

1M Return1.04%

Fixed assets turnover ratio

Value7895.57

Score3/3

Weight2.13%

1M Return1.06%

Cost of sales ratio (%)

Value70.31

Score3/3

Weight9.57%

1M Return4.32%

Asset-MV

Value-0.49

Score2/3

Weight31.99%

1M Return12.22%

Cash-MV

Value-0.09

Score2/3

Weight14.70%

1M Return5.94%

Is AURA undervalued or overvalued?

AURA scores 3.65/10 on fundamentals and holds a Fair valuation at present. Backed by its -73.52% ROE, 0.00% net margin, -4.04 P/E ratio, 3.13 P/B ratio, and -0.57% earnings growth, these metrics solidify its Netural investment rating.